Enhanced apomorphine sensitivity and increased binding of dopamine D 2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297

Synapse

Volumn 62, Issue 1, 2008, Pages 40-49

  Flores Tochihuitl, Julia ^a,b   Vargas, Guillermo ^a   Morales Medina, Julio Cesar ^a   Rivera, Gustavo ^a   De La Cruz, Fidel ^b   Zamudio, Sergio ^b   Flores, Gonzalo ^a  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

(+) S14297; Attention deficit hyperactive disorder; Dopamine D3 antagonist; Dopamine receptors; Locomotion

Indexed keywords

7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; APOMORPHINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTORADIOGRAPHY; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; FEMALE; LOCOMOTION; MALE; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; NUCLEUS ACCUMBENS; PERINATAL PERIOD; PREPUBERTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; APOMORPHINE; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 36348996582     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20463     Document Type: Article

References (60)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. 1996. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. Alquicer G, Silva-Gomez AB, Peralta F, Flores G. 2004. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci 22:103-111.
3. Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ. 1998. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287:187-197.
4. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P. 2003. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762-767.
5. Buckland PR, O'Donovan MC, McGuffin P. 1992. Changes in dopamine D1, D2, and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 106:479-483.
6. Buckland PR, O'Donovan MC, McGuffin P. 1993. Both splicing variants of the dopamine D2 receptor mRNA are up-regulated by antipsychotic drugs. Neurosci Lett 150:25-28.
7. Burt DR, Creese I, Snyder SH. 1977. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328.
8. Deutch AY, Goldstein M, Baldino F, Jr, Roth RH. 1988. Telencephalic projections of the A8 dopamine cell group. Ann N Y Acad Sci 537:27-50.
9. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P. 2000. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677-8684.
10. Diaz-Romero M, Arias-Montano JA, Eguibar JR, Flores G. 2005. Enhanced binding of dopamine D1 receptors in caudate-putamen subregions in High-Yawning Sprague-Dawley rats. Synapse 56:69-73.
11. Eilam D, Szechtman H. 1989. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161:151-157.
12. Ekman A, Nissbrandt H, Heilig M, Dijkstra D, Eriksson E. 1998. Central administration of dopamine D3 receptor antisense to rat: Effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn Schmiedebergs Arch Pharmacol 358:342-350.
13. Ernst AM. 1967. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10:316-323.
14. Flores G, Barbeau D, Quirion R, Srivastava LK. 1996. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 16:2020-2026.
15. Flores G, Flores J, Mena R, Valencia J. 2002. Mutant Taiep rats exhibit an increase in D1 binding in basal ganglia. Brain Res 956:24-29.
16. Flores G, Alquicer G, Silva-Gomez AB, Zaldivar G, Stewart J, Quirion R, Srivastava LK. 2005a. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in postpubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 133:463-470.
17. Flores G, Silva-Gomez AB, Ibanez O, Quirion R, Srivastava LK. 2005b. Comparative behavioral changes in postpubertal rats after neonatal excitotoxic lesions of the ventral hippocampus and the prefrontal cortex. Synapse 56:147-153.
18. Frantz K, Babcock D, Van Hartesveldt C. 1996. The locomotor effects of a putative dopamine D3 receptor agonist in developing rats. Eur J Pharmacol 302:1-6.
19. Gingrich JA, Caron MG. 1993. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299-321.
20. Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. 1995. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913.
21. Grillner P, Mercuri NB. 2002. Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons. Behav Brain Res 130:149-169.
22. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. 1997. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54:225-232.
23. Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S. 2001. Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev Med Child Neurol 43:755-760.
24. Joseph JD, Wang YM, Miles PR, Budygin EA, Picetti R, Gainetdinov RR, Caron MG, Wightman RM. 2002. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 112:39-49.
25. Juarez I, De La Cruz F, Zamudio S, Flores G. 2005. Cesarean plus anoxia at birth induces hyperresponsiveness to locomotor activity by dopamine D2 agonist. Synapse 58:236-242.
26. Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ. 1998. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci 18:2231-2238.
27. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. 2000. Dopamine D3 receptor gene expression in the shell of nucleus accumbens is increased by chronic antidepressant treatment. Mol Psychiatry 5:229.
28. Le Foll B, Schwartz JC, Sokoloff P. 2000. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 15:140-146.
29. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P. 1992. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159.
30. Levesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz JC. 1995. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719-1723.
31. Levesque M, Parent A. 1998. Axonal arborization of corticostriatal and corticothalamic fibers arising from prelimbic cortex in the rat. Cereb Cortex 8:602-613.
32. McGonigle P, Boyson SJ, Reuter S, Molinoff PB. 1989. Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse 3:74-82.
33. Meador-Woodruff JH. 1994. Update on dopamine receptors. Ann Clin Psychiatry 6:79-90.
34. Meador-Woodruff JH, Damask SP, Watson SJ, Jr. 1994. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 91:8297-8301.
35. Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL. 1994. S14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol 260:R3-R5.
36. Millan MJ, Gressier H, Brocco M. 1997. The dopamine D3 receptor antagonist, (+)-S14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7-R9.
37. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M. 2004. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: A combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 174:341-357.
38. Mittleman G, LeDuc PA, Whishaw IQ. 1993. The role of D1 and D2 receptors in the heightened locomotion induced by direct and indirect dopamine agonists in rats with hippocampal damage: An animal analogue of schizophrenia. Behav Brain Res 55:253-267.
39. Neisewander JL, Lucki I, McGonigle P. 1991. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J Pharmacol Exp Ther 257:850-860.
40. Nissbrandt H, Ekman A, Eriksson E, Heilig M. 1995. Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 6:573-576.
41. Niznik HB, Van Tol HH. 1992. Dopamine receptor genes: New tools for molecular psychiatry. J Psychiatry Neurosci 17:158-180.
42. Norman AB, Battaglia G, Creese I. 1987. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: A key to receptor regulatory mechanisms. J Neurosci 7:1484-1491.
43. Paxinos G, Watson C. 1996. The rat brain stereotaxic coordinates, 2a. ed. London: Academic Press.
44. Perachon S, Betancur C, Pilon C, Rostene W, Schwartz JC, Sokoloff P. 2000. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport 11:221-225.
45. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. 1999. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400:371-375.
46. Reynolds SM, Zahm DS. 2005. Specificity in the projections of prefrontal and insular cortex to ventral striatopallidum and the extended amygdala. J Neurosci 25:11757-11767.
47. Seeman P, Grigoriadis D. 1987. Dopamine receptors in brain and periphery. Neurochem Int 10:1-25.
48. Sesack SR, Pickel VM. 1992. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320:145-160.
49. Sibley DR, Monsma FJ, Jr. 1992. Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69.
50. Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz JC. 1992. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659-666.
51. Sovago J, Farde L, Halldin C, Schukin E, Schou M, Laszlovszky I, Kiss B, Gulyas B. 2005. Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756. Brain Res Bull 67:219-224.
52. Stanwood GD, Lucki I, McGonigle P. 2000. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J Pharmacol Exp Ther 295:1232-1240.
53. Svensson K, Carlsson A, Waters N. 1994. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect 95:71-74.
54. Swarzenski BC, O'Malley KL, Todd RD. 1996. PTX-sensitive regulation of neurite outgrowth by the dopamine D3 receptor. Neuroreport 7:573-576.
55. Tarazi FI, Florijn WJ, Creese I. 1997. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78:985-996.
56. Tremblay M, Rouillard C, Levesque D. 1997. Dopamine D3 receptor antisense reduces neuropeptide mRNA levels in rat nucleus accumbens. Neuroreport 8:3901-3905.
57. Tremblay M, Rouillard C, Levesque D. 1998. The antisense strategy applied to the study of dopamine D3 receptor functions in rat forebrain. Prog Neuropsychopharmacol Biol Psychiatry 22:857-882.
58. Tremblay M, Rouillard C, Levesque D. 1999. Dopamine D3 receptor antisense administration reduces basal c-fos and NGFI-B mRNA levels in the rat forebrain. Synapse 32:51-57.
59. Viggiano D, Vallone D, Ruocco LA, Sadile AG. 2003. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci Biobehav Rev 27:683-689.
60. Wang W, Hahn KH, Bishop JF, Gao DQ, Jose PA, Mouradian MM. 1996. Up-regulation of D3 dopamine receptor mRNA by neuroleptics. Synapse 23:232-235.